Accepted Article This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.17254 This article is protected by copyright. All rights reserved. DR THIBAULT MAHÉVAS (Orcid ID : 0000-0001-5951-1831) Article type : Case Report Corresponding author mail id: thibault.mahevas@gmail.com Dramatic response to brentuximab vedotin in a refractory non-transformed CD30-negative mycosis fungoides allowing allogeneic stem cells transplantation and long-term complete remission. T. Mahévas 1 , C. Ram-Wolff 1 , M. Battistella 2,4 , M. D. V. Pennamen 2 , J. Rivet 2 , P. Brice 3,4 , M. Bagot 1,4 1 Dermatology Department, AP-HP Hôpital Saint-Louis, Paris, 2 Pathology Department, AP-HP Hôpital Saint-Louis, Paris 3 Hematology Department, AP-HP, Saint-Louis Hospital, Paris, 4 Sorbonne Paris Cité Université Paris Diderot, Paris Funding Sources : None Conflicts of interest : M Bagot: Takeda scientific board M Battistella : Consulting for Innate Pharma, Speaker for Takeda Key words : mycosis fungoides, brentuximab vedotin, allogeneic stem cells transplantation What is already known about this topic? The efficiency of brentuximab vedotin in refractory CD30- positive cutaneous T-cell lymphoma is now well established. Erythrodermic forms of MF are challenging to treat, and allogeneic stem cell transplantation is sometimes required.